Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot tested for Tough-to-Treat blood cancer

NCT ID NCT06223516

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called etentamig (ABBV-383) for adults with multiple myeloma, a blood cancer, that has returned or is not responding to current treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for side effects. About 55 participants will receive the drug as an injection under the skin or through an IV over about 3 years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atrium Health Wake Forest Baptist Medical Center /ID# 260807

    ACTIVE_NOT_RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Hadassah Medical Center-Hebrew University /ID# 261446

    RECRUITING

    Jerusalem, Jerusalem, 91120, Israel

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 265286

    ACTIVE_NOT_RECRUITING

    Nagoya, Aichi-ken, 466-8650, Japan

  • Kindai University Hospital /ID# 266016

    ACTIVE_NOT_RECRUITING

    Sakai-shi, Osaka, 590-0197, Japan

  • Mayo Clinic - Rochester /ID# 262807

    ACTIVE_NOT_RECRUITING

    Rochester, Minnesota, 55905-0001, United States

  • Mayo Clinic Arizona /ID# 260799

    ACTIVE_NOT_RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Hospital Jacksonville /ID# 262808

    ACTIVE_NOT_RECRUITING

    Jacksonville, Florida, 32224, United States

  • Sylvester Comprehensive Cancer Center /ID# 260798

    ACTIVE_NOT_RECRUITING

    Miami, Florida, 33136-1002, United States

  • Tel Aviv Sourasky Medical Center /ID# 261525

    ACTIVE_NOT_RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 261699

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • Universitaetsklinikum Frankfurt /ID# 260442

    ACTIVE_NOT_RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 260444

    ACTIVE_NOT_RECRUITING

    Hamburg, 20246, Germany

  • Universitaetsklinikum Koeln /ID# 260445

    COMPLETED

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050

    ACTIVE_NOT_RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Wisconsin Medical Center /ID# 261085

    COMPLETED

    Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA